227 related articles for article (PubMed ID: 19145444)
41. A comparison between general rheumatologists and scleroderma experts with respect to following systemic sclerosis guidelines.
Reed J; Pope J
Clin Exp Rheumatol; 2015; 33(4 Suppl 91):S40-6. PubMed ID: 26121522
[TBL] [Abstract][Full Text] [Related]
42. Type I interferon dysregulation in Systemic Sclerosis.
Skaug B; Assassi S
Cytokine; 2020 Aug; 132():154635. PubMed ID: 30685202
[TBL] [Abstract][Full Text] [Related]
43. [An update on systemic sclerosis].
Kowal-Bielecka O
Ann Acad Med Stetin; 2010; 56 Suppl 1():80-2. PubMed ID: 21365948
[TBL] [Abstract][Full Text] [Related]
44. Scleroderma lung disease, variation in screening, diagnosis and treatment practices between rheumatologists and respiratory physicians.
Mangat P; Conron M; Gabbay E; Proudman SM;
Intern Med J; 2010 Jul; 40(7):494-502. PubMed ID: 19460060
[TBL] [Abstract][Full Text] [Related]
45. [Systemic sclerosis-clinical picture, diagnosis, and treatment].
Becker MO; Distler O; Maurer B
Hautarzt; 2019 Sep; 70(9):723-741. PubMed ID: 31384958
[TBL] [Abstract][Full Text] [Related]
46. New therapeutic strategies for systemic sclerosis--a critical analysis of the literature.
Zandman-Goddard G; Tweezer-Zaks N; Shoenfeld Y
Clin Dev Immunol; 2005 Sep; 12(3):165-73. PubMed ID: 16295521
[TBL] [Abstract][Full Text] [Related]
47. Management of systemic sclerosis: the art and science.
Stone JH; Wigley FM
Semin Cutan Med Surg; 1998 Mar; 17(1):55-64. PubMed ID: 9512108
[TBL] [Abstract][Full Text] [Related]
48. Using Autoantibodies and Cutaneous Subset to Develop Outcome-Based Disease Classification in Systemic Sclerosis.
Nihtyanova SI; Sari A; Harvey JC; Leslie A; Derrett-Smith EC; Fonseca C; Ong VH; Denton CP
Arthritis Rheumatol; 2020 Mar; 72(3):465-476. PubMed ID: 31682743
[TBL] [Abstract][Full Text] [Related]
49. Interactions between rheumatologists and cardio-/pulmonologists in the assessment and use of outcome measures in pulmonary arterial hypertension related to systemic sclerosis.
Huscher D; Pittrow D; Distler O; Denton CP; Foeldvari I; Humbert M; Matucci-Cerinic M; Kowal-Bielecka O; Avouac J; Behrens F; Nash P; Opitz CF; Rubin LJ; Seibold JR; Strand V; Furst DE;
Clin Exp Rheumatol; 2010; 28(2 Suppl 58):S47-52. PubMed ID: 20576214
[TBL] [Abstract][Full Text] [Related]
50. Major lung complications of systemic sclerosis.
Denton CP; Wells AU; Coghlan JG
Nat Rev Rheumatol; 2018 Sep; 14(9):511-527. PubMed ID: 30111804
[TBL] [Abstract][Full Text] [Related]
51. A practical approach to the evaluation and management of gastrointestinal symptoms in patients with systemic sclerosis.
Kaniecki T; Abdi T; McMahan ZH
Best Pract Res Clin Rheumatol; 2021 Sep; 35(3):101666. PubMed ID: 33676855
[TBL] [Abstract][Full Text] [Related]
52. Risk factors for severity and manifestations in systemic sclerosis and prediction of disease course.
Becker MO; Riemekasten G
Expert Rev Clin Immunol; 2016; 12(2):115-35. PubMed ID: 26558747
[TBL] [Abstract][Full Text] [Related]
53. Systemic sclerosis: a critical digest of the recent literature.
Tani C; Bellando Randone S; Guiducci S; Della Rossa A
Clin Exp Rheumatol; 2013; 31(2 Suppl 76):172-9. PubMed ID: 23910620
[TBL] [Abstract][Full Text] [Related]
54. Interstitial Lung Disease in Patients With Systemic Sclerosis: Toward Personalized-Medicine-Based Prediction and Drug Screening Models of Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD).
Khedoe P; Marges E; Hiemstra P; Ninaber M; Geelhoed M
Front Immunol; 2020; 11():1990. PubMed ID: 33013852
[TBL] [Abstract][Full Text] [Related]
55. Use of biologics and other novel therapies for the treatment of systemic sclerosis.
Bruni C; Praino E; Allanore Y; Distler O; Gabrielli A; Iannone F; Matucci-Cerinic M
Expert Rev Clin Immunol; 2017 May; 13(5):469-482. PubMed ID: 27899043
[TBL] [Abstract][Full Text] [Related]
56. Targeting interferons as a strategy for systemic sclerosis treatment.
Ciechomska M; Skalska U
Immunol Lett; 2018 Mar; 195():45-54. PubMed ID: 29106987
[TBL] [Abstract][Full Text] [Related]
57. Endothelial to mesenchymal transition (EndoMT) in the pathogenesis of Systemic Sclerosis-associated pulmonary fibrosis and pulmonary arterial hypertension. Myth or reality?
Jimenez SA; Piera-Velazquez S
Matrix Biol; 2016 Apr; 51():26-36. PubMed ID: 26807760
[TBL] [Abstract][Full Text] [Related]
58. How I treat patients with systemic sclerosis in clinical practice.
Rossi D; Zanatta E; Marson P; Sciascia S; Polito P; Roccatello D; Cozzi F
Autoimmun Rev; 2017 Oct; 16(10):1024-1028. PubMed ID: 28778710
[TBL] [Abstract][Full Text] [Related]
59. iNOS Activity Is Required for the Therapeutic Effect of Mesenchymal Stem Cells in Experimental Systemic Sclerosis.
Maria ATJ; Rozier P; Fonteneau G; Sutra T; Maumus M; Toupet K; Cristol JP; Jorgensen C; Guilpain P; Noël D
Front Immunol; 2018; 9():3056. PubMed ID: 30622540
[No Abstract] [Full Text] [Related]
60. Disease activity indices in systemic sclerosis: a systematic literature review.
Melsens K; De Keyser F; Decuman S; Piette Y; Vandecasteele E; Smith V
Clin Exp Rheumatol; 2016; 34 Suppl 100(5):186-192. PubMed ID: 27385265
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
